OBJECTIVES: Biologic agents are mainly used for the treatment of rheumatic diseases; particularly rheumatoid arthritis is considered one of the priority problems of public health in Mexico. This analysis aims to compare Mexican public expenditure on tumor necrosis factor inhibitors (anti-TNF) in two main health-care providers for salaried workers and to estimate the budget impact of the incorporation of golimumab as an alternative anti-TNF therapy. METHODS: A descriptive analysis was developed based on published data of prescribing information for each anti-TNF agent (dosage per patient for rheumatoid arthritis) and on national tenders to obtain the acquisition price for each therapy. The two institutions evaluated were the Mexican Social Security Institute (IMSS) and the Institute of Social Security and Services of State Workers (ISSSTE) covering ~50% and ~11% of Mexican population, respectively. The data obtained about the purchases of anti-TNF agents during the period 2014-2016 was used to calculate the annual number of patients in treatment. Based on these calculations, an extrapolation was performed to estimate the number of patients in treatment during 2017-2019 periods. Finally, a budget impact model was developed to analyze the impact of the penetration of golimumab in both institutions. Costs are expressed in 2016USD ($1USD=$20MXN). RESULTS:  In both institutions the anti-TNF with the highest expenditure was adalimumab, followed by etanercept (25mg and 50mg) and infliximab to the last. According to total population covered, average number of patients in anti-TNF agents’ treatment is 0.4% and 1.1% for IMSS and ISSSTE, respectively. With the incorporation of golimumab in 10% of patients at IMSS the total savings for 2017-2019 period would be $2.5 million and for ISSSTE $2.0 million. CONCLUSIONS:  The incorporation of golimumab at IMSS and ISSSTE formularies represents potential savings that could lead to an increase in the number of patients who benefit from these anti-TNF therapies.